Modulation of feeding by chronic rAAV expression of a relaxin-3 peptide agonist in rat hypothalamus

Gene Therapy

Volumn 20, Issue 7, 2013, Pages 703-716

  Ganella, D E ^a   Callander, G E ^a,b   Ma, S ^a   Bye, C R ^a   Gundlach, A L ^a   Bathgate, R A D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Constitutive peptide secretion; Feeding; Hypothalamus; Recombinant adeno associated virus; relaxin 3 and RXFP3

Indexed keywords

FIBRONECTIN; GONADORELIN; MESSENGER RNA; NEUROPEPTIDE Y; OXYTOCIN; PARVOVIRUS VECTOR; RELAXIN 3; VASOPRESSIN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT; BRAIN STEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DESENSITIZATION; FOOD INTAKE; HYPOTHALAMUS; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MALE; NEUROMODULATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPORTER GENE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; WEIGHT GAIN;

ANIMALS; BODY WEIGHT; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; EATING; EATING DISORDERS; FEEDING BEHAVIOR; FIBRONECTINS; HEK293 CELLS; HUMANS; HYPOTHALAMUS; MALE; NERVE TISSUE PROTEINS; OXYTOCIN; PEPTIDES; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RELAXIN;

ADENO-ASSOCIATED VIRUS; RATTUS;

EID: 84880226636     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.83     Document Type: Article

References (74)

1. Bathgate RAD, Samuel CS, Burazin TCD, Layfield S, Claasz AA, Reytomas IGT et al. Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. Novel members of the relaxin peptide family. J Biol Chem 2002; 277: 1148-1157.
2. Burazin TCD, Bathgate RAD, Macris M, Layfield S, Gundlach AL, Tregear G. Restricted, but abundant, expression of the novel rat gene-3 (R3) relaxin in the dorsal tegmental region of brain. J Neurochem 2002; 82: 1553-1557.
3. Tanaka M, Iijima N, Miyamoto Y, Fukusumi S, Itoh Y, Ozawa H et al. Neurons expressing relaxin 3/INSL in the nucleus incertus respond to stress. Eur J Neurosci 2005; 21: 1659-1670.
4. Smith CM, Shen PJ, Banerjee A, Bonaventure P, Ma S, Bathgate RAD et al. Distribution of relaxin-3 and RXFP3 within arousal, stress, affective, and cognitive circuits of mouse brain. J Comp Neurol 2010; 518: 4016-4045.
5. Ryan PJ, Ma S, Olucha-Bordonau FE, Gundlach AL. Nucleus incertus-an emerging modulatory role in arousal, stress and memory. Neurosci Biobehav Rev 2011; 35: 1326-1341.
6. Ma S, Bonaventure P, Ferraro T, Shen PJ, Burazin TCD, Bathgate RAD et al. Relaxin-in GABA projection neurons of nucleus incertus suggests widespread influence on forebrain circuits via G-protein-coupled receptor-135 in the rat. Neuroscience 2007; 144: 165-190.
7. Goto M, Swanson LW, Canteras NS. Connections of the nucleus incertus. J Comp Neurol 2001; 438: 86-122.
8. Olucha-Bordonau FE, Teruel V, Barcia-Gonzalez J, Ruiz-Torner A, Valverde-Navarro AA, Martinez-Soriano F. Cytoarchitecture and efferent projections of the nucleus incertus of the rat. J Comp Neurol 2003; 464: 62-97.
9. Liu C, Eriste E, Sutton S, Chen J, Roland B, Kuei C et al. Identification of relaxin-3/ INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J Biol Chem 2003; 278: 50754-50764.
10. Sutton SW, Bonaventure P, Kuei C, Roland B, Jingcai C, Nepomuceno D et al. Distribution of G-protein-coupled receptor (GPCR)135 binding sites and receptor mRNA in the rat brain suggests a role for relaxin-3 in neuroendocrine and sensory processing. Neuroendocrinology 2004; 80: 298-307.
11. Banerjee A, Shen PJ, Ma S, Bathgate RA, Gundlach AL. Swim stress excitation of nucleus incertus and rapid induction of relaxin-3 expression via CRF1 activation. Neuropharmacology 2009; 58: 145-155.
12. Ma S, Olucha-Bordonau FE, Hossain MA, Lin F, Kuei C, Liu CL et al. Modulation of hippocampal theta oscillations and spatial memory by relaxin-3 neurons of the nucleus incertus. Learn Mem 2009; 16: 730-742.
13. McGowan BMC, Stanley SA, Smith KL, White NE, Connolly MM, Thompson EL et al. Central relaxin-3 administration causes hyperphagia in male wistar rats. Endocrinology 2005; 146: 3295-3300.
14. Smith CM, Ryan PJ, Hosken IT, Ma S, Gundlach AL. Relaxin-3 systems in the brain-the first years. J Chem Neuroanat 2011; 42: 262-275.
15. Liu C, Chen J, Sutton S, Roland B, Kuei C, Farmer N et al. Identification of relaxin-3/ INSL7 as a ligand for GPCR142. J Biol Chem 2003; 278: 50765-50770.
16. Sudo S, Kumagai J, Nishi S, Layfield S, Ferraro T, Bathgate RAD et al. H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2. J Biol Chem 2003; 278: 7855-7862.
17. Liu C, Chen J, Kuei C, Sutton S, Nepomuceno D, Bonaventure P et al. Relaxin-3/ insulin-like peptide chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G proteincoupled receptor 7. Mol Pharmacol 2005; 67: 231-240.
18. Liu C, Kuei C, Sutton S, Chen J, Bonaventure P, Wu J et al. INSL5 is a high affinity specific agonist for GPCR142 (GPR100). J Biol Chem 2005; 280: 292-300.
19. McGowan BM, Stanley SA, Donovan J, Thompson EL, Patterson M, Semjonous NM et al. Relaxin-3 stimulates the hypothalamic-pituitary-gonadal axis. Am J Physiol Endocrinol Metab 2008; 295: E278-E286.
20. McGowan BM, Stanley SA, Smith KL, Minnion JS, Donovan J, Thompson EL et al. Effects of acute and chronic relaxin-3 on food intake and energy expenditure in rats. Regul Pept 2006; 136: 72-77.
21. McGowan BM, Stanley SA, White NE, Spangeus A, Patterson M, Thompson EL et al. Hypothalamic mapping of orexigenic action and Fos-like immunoreactivity following relaxin-3 administration in male Wistar rats. Am J Physiol Endocrinol Metab 2007; 292: E913-E919.
22. Kuei C, Sutton S, Bonaventure P, Pudiak C, Shelton J, Zhu J et al. R3(B{Delta}23 27)R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7: in vitro and in vivo characterization. J Biol Chem 2007; 282: 25425-25435.
23. de Backer M, Fitzsimons C, Brans M, Luijendijk M, Garner K, Vreugdenhil E et al. An adeno-associated viral vector transduces the rat hypothalamus and amygdala more efficient than a lentiviral vector. BMC Neurosci 2010; 11: 81.
24. Tiesjema B, la Fleur SE, Luijendijk MC, Adan RA. Sustained NPY overexpression in the PVN results in obesity via temporarily increasing food intake. Int J Obes 2009; 17: 1448-1450.
25. McCown TJ. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol Ther 2006; 14: 63-68.
26. Noe F, Pool AH, Nissinen J, Gobbi M, Bland R, Rizzi M et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008; 131: 1506-1515.
27. Bathgate RAD, Lin F, Hanson NF, Otvos L, Guidolin A, Giannakis C et al. Relaxin-3: Improved synthesis strategy and demonstration of its high-affinity interaction with the relaxin receptor LGR7 both in vitro and in vivo. Biochemistry 2006; 45: 1043-1053.
28. Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 1997; 327: 625-635.
29. Ruoslahti E. Fibronectin and its receptors. Annu Rev Biochem 1988; 57: 375-413.
30. Foti S, Haberman RP, Samulski RJ, McCown TJ. Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Therapy 2007; 14: 1534-1536.
31. Foti SB, Samulski RJ, McCown TJ. Delivering multiple gene products in the brain from a single adeno-associated virus vector. Gene Therapy 2009; 16: 1314-1319.
32. Schafer MKH, Day R, Cullinan WE, Chretien M, Seidah NG, Watson SJ. Geneexpression of prohormone and proprotein convertases in the rat CNS-a comparative in situ hybridization analysis. J Neurosci 1993; 13: 1258-1279.
33. Regev L, Ezrielev E, Gershon E, Gil S, Chen A. Genetic approach for intracerebroventricular delivery. Proc Natl Acad Sci USA 2010; 107: 4424-4429.
34. Hida T, Takahashi E, Shikata K, Hirohashi T, Sawai T, Seiki T et al. Chronic intracerebroventricular administration of relaxin-3 increases body weight in rats. J Recept Signal Transduct 2006; 26: 147-158.
35. Bathgate RAD, Lekgabe ED, McGuane JT, Su Y, Pham T, Ferraro T et al. Adenovirusmediated delivery of relaxin reverses cardiac fibrosis. Mol Cell Endocrinol 2008; 280: 30-38.
36. Chen WB, Shields TS, Stork PJS, Cone RD. A colorimetric assay for measuring activation of G(S)-coupled and G(Q)-coupled signaling pathways. Anal Biochem 1995; 226: 349-354.
37. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.
38. Veldwijk MR, Topaly J, Laufs S, Hengge UR, Wenz F, Zeller WJ et al. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther 2002; 6: 272-278.
39. de Backer MWA, Brans MAD, Luijendijk MC, Garner KM, Adan RAH. Optimization of adeno-associated viral vector-mediated gene delivery to the hypothalamus. Hum Gene Ther 2010; 21: 673-682.
40. Cowley MA, Smart JL, Rubinstein M, Cordan MG, Diano S, Horvath TL et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001; 411: 480-484.
41. Korner J, Savontaus E, Chua SC, Leibel RL, Wardlaw SL. Leptin regulation of AgRP and NPY mRNA in the rat hypothalamus. J Neuroendocrinol 2001; 13: 959-966.
42. Olszewski PK, Klockars A, Schioth HB, Levine AS. Oxytocin as feeding inhibitor: maintaining homeostasis in consummatory behavior. Pharmacol Biochem Behav 2010; 97: 47-54.
43. Schrier RW, Berl T, Anderson RJ. Osmotic and non-osmotic control of vasopressin release. Am J Physiol 1979; 236: F321-F332.
44. Wilkinson TN, Bathgate RAD. The Evolution of the Relaxin Peptide Family and their Receptors: Relaxin and Related Peptides. Springer-Verlag: Berlin, 2007, pp 1-13.
45. Chen J, Kuei C, Sutton SW, Bonaventure P, Nepomuceno D, Eriste E et al. Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species. J Pharmacol Exp Ther 2005; 312: 83-95.
46. Hossain MA, Bathgate RAD, Rosengren KJ, Shabanpoor F, Zhang SD, Lin F et al. The structural and functional role of the B-chain C-terminal arginine in the relaxin-peptide antagonist, R3(B Delta 23-27)R/I5. Chem Biol Drug Des 2009; 73: 46-52.
47. Fitzsimons HL, Bland RJ, During MJ. Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods 2002; 28: 227-236.
48. Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 2011; 22: 1143-1153.
49. Haugaard-Kedstrom LM, Shabanpoor F, Hossain MA, Clark RJ, Ryan PJ, Craik DJ et al. Design, synthesis, and characterization of a single-chain peptide antagonist for the relaxin-3 receptor RXFP3. J Am Chem Soc 2011; 133: 4965-4974.
50. Tiesjema B, la Fleur SE, Luijendijk MC, Brans MA, Lin EJ, During MJ et al. Viral mediated neuropeptide Y expression in the rat paraventricular nucleus results in obesity. Int J Obes 2007; 15: 2424-2435.
51. Tiesjema B, Adan RA, Luijendijk MC, Kalsbeek A, la Fleur SE. Differential effects of recombinant adeno-associated virus-mediated neuropeptide Y overexpression in the hypothalamic paraventricular nucleus and lateral hypothalamus on feeding behavior. J Neurosci 2007; 27: 14139-14146.
52. de Backer MWA, la Fleur SE, Brans MAD, van Rozen AJ, Luijendijk MCM, Merkestein M et al. Melanocortin receptor-mediated effects on obesity are distributed over specific hypothalamic regions. Int J Obes 2011; 35: 629-641.
53. Small CJ, Liu YL, Stanley SA, Connoley IP, Kennedy A, Stock MJ et al. Chronic CNS administration of Agouti-related protein (AgRP) reduces energy expenditure. Int J Obes Relat Metab Disord 2003; 27: 530-533.
54. Billington CJ, Briggs JE, Grace M, Levine AS. Effects of intracerebroventricular injection of neuropeptide-Y on energy-metabolism. Am J Physiol 1991; 260: R321-R327.
55. Stanley BG, Daniel DR, Chin AS, Leibowitz SF. Paraventricular nucleus injections of peptide-YY and neuropeptide-Y preferentially enhance carbohydrate ingestion. Peptides 1985; 6: 1205-1211.
56. Klein RL, Hamby ME, Gong Y, Hirko AC, Wang S, Hughes JA et al. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol 2002; 176: 66-74.
57. Yulyaningsih E, Zhang L, Herzog H, Sainsbury A. NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol 2011; 163: 1170-1202.
58. Kamiji MM, Inui A. NPY Y(2) and Y(4) receptors selective ligands: promising anti-obesity drugs? Curr Top Med Chem 2007; 7: 1734-1742.
59. Wu G, Feder A, Wegener G, Bailey C, Saxena S, Charney D et al. Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin Ther Targets 2011; 15: 1317-1331.
60. Richichi C, Lin E-JD, Stefanin D, Colella D, Ravizza T, Grignaschi G et al. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 2004; 24: 3051-3059.
61. Ganella DE, Ryan PJ, Bathgate RA, Gundlach AL. Increased feeding and body weight gain in rats after acute and chronic activation of RXFP3 by relaxin-3 and receptor-selective peptides: functional and therapeutic implications. Behav Pharmacol 2012; 23: 516-525.
62. Olson BR, Drutarosky MD, Chow MS, Hruby VJ, Stricker EM, Verbalis JG. Oxytocin and an oxytocin agonist administered centrally decrease food-intake in rats. Peptides 1991; 12: 113-118.
63. Gaetani S, Fu J, Cassano T, Dipasquale P, Romano A, Righetti L et al. The fatinduced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin. J Neurosci 2010; 30: 8096-8101.
64. Olson BR, Drutarosky MD, Stricker EM, Verbalis JG. Brain oxytocin receptor antagonism blunts the effects of anorexigenic treatment in rats-evidence for central oxytocin inhibition of food-intake. Endocrinology 1991; 129: 785-791.
65. Callander GE, Thomas WG, Bathgate RAD. Development and optimization of microRNA against relaxin-3. Ann NY Acad Sci 2009; 1160: 261-264.
66. Van Der Westhuizen ET, Sexton PM, Bathgate RAD, Summers RJ. Responses of GPCR135 to human gene 3 (H3) relaxin in CHO-KI cells determined by microphysiometry. Ann NY Acad Sci 2005; 1041: 332-337.
67. Haugaard-Jonsson LM, Hossain MA, Daly NL, Bathgate RAD, Wade JD, Craik DJ et al. Structure of the R3/I5 chimeric relaxin peptide, a selective GPCR135 and GPCR142 agonist. J Biol Chem 2008; 283: 23811-23818.
68. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003; 7: 839-850.
69. Paxinos G, Watson C. The Rat Brain In Stereotaxic Coordinates. Academic Press: New York, 1986.
70. Callander GE, Ma S, Ganella DE, Wimmer VC, Gundlach AL, Thomas WG et al. Silencing relaxin-3 in nucleus incertus of adult rodents: a viral vector-based approach to investigate neuropeptide function. PLoS One 2012; 7: e42300.
71. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-DDC) method. Methods 2001; 25: 402-408.
72. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C-T method. Nat Protoc 2008; 3: 1101-1108.
73. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press: Totowa, NJ, 2000, pp 365-386.
74. Lindblom J, Haitina T, Fredriksson R, Schioth HB. Differential regulation of nuclear receptors, neuropeptides and peptide hormones in the hypothalamus and pituitary of food restricted rats. Mol Brain Res 2005; 133: 37-46.